Apolipoprotein E Genotyping and Alzheimer Disease Risk Assessment

Apolipoprotein E (APOE) genotyping has become a cornerstone in the evaluation of individual susceptibility to Alzheimer disease (AD). Three common alleles—ε2, ε3 and ε4—encode protein isoforms that differ by single amino-acid substitutions and influence lipid transport, neuronal repair and amyloid-β clearance. Carriage of the ε4 allele is associated with increased risk and earlier onset of AD, whereas ε2 confers a modest protective effect. Genotyping technologies ranging from restriction-enzyme assays to real-time PCR and immunoturbidimetric platforms enable determination of APOE status in clinical and research settings. Integration of APOE genotype into risk models improves prognostication, informs patient stratification in prevention trials and underpins precision-medicine strategies aimed at delaying symptom onset. Global allele frequency variations underscore the need for population-specific reference data, and reliable genotyping of archived tissue samples extends opportunities for retrospective cohort analyses. Advances in assay automation, cost-effectiveness and compatibility with clinical chemistry analyzers have driven broader implementation of APOE testing for both individual risk assessment and large-scale epidemiological studies.

Research from Nature Portfolio

A novel immunoturbidimetric assay adapted for automated chemistry analyzers has been validated for rapid detection of the ApoE4 isoform in plasma. Following international quality standards, this latex-enhanced method demonstrated diagnostic accuracy comparable to polymerase chain reaction, with minimal sample preprocessing, full compatibility with high-throughput clinical analyzers and a 99 % concordance in identifying ε4 carriers. Its low cost and integration into routine blood panels facilitate seamless identification of high-risk individuals and support stratification in both clinical trials and preventative interventions.

An alternative isotyping technique exploits the differential binding affinity of ApoE4 to polystyrene surfaces coupled with a monoclonal anti-ApoE4 reporter antibody. This method enables direct protein-level detection of the ε4 isoform in biological fluids without nucleic acid amplification. Although discrimination between heterozygous and homozygous ε4 genotypes remains unresolved, the assay’s robustness, speed and adaptability to turbidimetric platforms point to a future of inexpensive, clinically implementable screens for population-level risk stratification and patient enrolment in amyloid-targeting studies.

Apolipoprotein E Genotyping and Alzheimer Disease Risk Assessment publication trend

The graph below shows the total number of articles in apolipoprotein e genotyping and alzheimer disease risk assessment across all publications each year (not limited to Nature Index journals).

Technical terms

Apolipoprotein E (APOE): A 34 kDa glycoprotein involved in lipid transport and neuronal repair whose gene is polymorphic at two key sites, yielding ε2, ε3 and ε4 variants.

Isoform: A protein variant arising from gene polymorphisms that differ in amino-acid sequence and functional properties.

Allele-specific PCR: A polymerase chain reaction technique using primers designed to selectively amplify specific gene variants.

Immunoturbidimetric assay: A method for quantifying proteins by measuring light scattering caused by antigen–antibody complexes.

Formalin-fixed, paraffin-embedded (FFPE) tissue: Biological specimens preserved in formalin and infiltrated with paraffin wax for long-term storage and histological analysis.

References

1. Apolipoprotein‐E genotyping in formalin‐fixed and paraffin‐embedded post‐mortem brain tissue. Brain Pathology (2024).
2. A rapid and cost-effective method for genotyping apolipoprotein E gene polymorphism. Molecular Neurodegeneration (2016).
3. A fast and cost-effective method for apolipoprotein E isotyping as an alternative to APOE genotyping for patient screening and stratification. Scientific Reports (2018).
4. Validation of a novel and accurate ApoE4 assay for automated chemistry analyzers. Scientific Reports (2020).
5. Should the ApoE genotype be a covariate for clinical trials in Alzheimer disease?. Alzheimer's Research & Therapy (2010).